MedPath

Bepotastine Besilate Ophthalmic Solution 1.5%

These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION. BEPOTASTINE Besilate Ophthalmic Solution 1.5% for topical ophthalmic use Initial U.S. Approval: 2009

Approved
Approval ID

f68306a9-80ec-4bc5-8c00-1e1328f21e36

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 21, 2023

Manufacturers
FDA

Alembic Pharmaceuticals Inc.

DUNS: 079288842

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Bepotastine Besilate Ophthalmic Solution 1.5%

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code62332-598
Application NumberANDA214588
Product Classification
M
Marketing Category
C73584
G
Generic Name
Bepotastine Besilate Ophthalmic Solution 1.5%
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateJuly 21, 2023
FDA Product Classification

INGREDIENTS (6)

BEPOTASTINE BESILATEActive
Quantity: 15 mg in 1 mL
Code: 6W18MO1QR3
Classification: ACTIB
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATEInactive
Code: 5QWK665956
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Bepotastine Besilate Ophthalmic Solution 1.5% - FDA Drug Approval Details